Clinical trial
A Phase 1, Dose-escalation, Placebo- and Active-Controlled Crossover Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB1934 and the Effect of Concomitant Proton Pump Inhibitor Administration in Healthy Volunteers
NCT04984525 is registered in ClinicalTrials.gov with Synlogic as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Dose-escalation, Placebo- and Active-Controlled Crossover Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB1934 and the Effect of Concomitant Proton Pump Inhibitor Administration in Healthy Volunteers
- Lead sponsor
- Synlogic
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 2, 2021
- Completion date
- December 10, 2021
- Enrollment
- 106 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy